Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):707–713. doi: 10.1128/aac.35.4.707

High-dose itraconazole in the treatment of severe mycoses.

P K Sharkey 1, M G Rinaldi 1, J F Dunn 1, T C Hardin 1, R J Fetchick 1, J R Graybill 1
PMCID: PMC245083  PMID: 1648887

Abstract

Eight patients with systemic mycoses and with prior treatment failures were treated with itraconazole (600 mg/day) for a mean duration of 5.5 months. All six patients without AIDS experienced improvement or stabilization of their fungal infections while receiving high-dose itraconazole, although two patients later experienced treatment failures, one by relapse and one by progression, on lower doses. Treatment failures also occurred in the two patients with AIDS and cryptococcal meningitis. The failures were associated with low serum itraconazole concentrations (less than 2.5 micrograms/ml) in both patients. All other patients had mean trough levels in serum above 5 micrograms/ml. One patient who was improving on 600 mg/day developed a progressive infection after reduction of the dose to 400 mg/day. Side effects included reversible adrenal insufficiency in one patient; severe hypokalemia, mild diastolic hypertension, and rhabdomyolysis in one patient; mild hypokalemia and hypertension in four other patients; and breast tenderness in one patient. The mean decrease in serum potassium during treatment was statistically significant (P = 0.05). Selected patients with severe systemic mycoses may benefit from prolonged high-dose itraconazole treatment. However, 600 mg/day may be approaching the upper limits of acceptable dosing for long-term treatment.

Full text

PDF
707

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodet C. A., 3rd, Jorgensen J. H., Drutz D. J. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol. 1985 Aug;22(2):157–160. doi: 10.1128/jcm.22.2.157-160.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S57–S63. doi: 10.1093/clinids/9.supplement_1.s57. [DOI] [PubMed] [Google Scholar]
  3. Borgers M., Van de Ven M. A. Degenerative changes in fungi after itraconazole treatment. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S33–S42. doi: 10.1093/clinids/9.supplement_1.s33. [DOI] [PubMed] [Google Scholar]
  4. Cauwenbergh G., De Doncker P., Stoops K., De Dier A. M., Goyvaerts H., Schuermans V. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S146–S152. doi: 10.1093/clinids/9.supplement_1.s146. [DOI] [PubMed] [Google Scholar]
  5. Craven P. C., Graybill J. R., Jorgensen J. H., Dismukes W. E., Levine B. E. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med. 1983 Feb;98(2):160–167. doi: 10.7326/0003-4819-98-2-160. [DOI] [PubMed] [Google Scholar]
  6. Denning D. W., Tucker R. M., Hanson L. H., Hamilton J. R., Stevens D. A. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989 Oct;149(10):2301–2308. [PubMed] [Google Scholar]
  7. Espinel-Ingroff A., Shadomy S., Gebhart R. J. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. doi: 10.1128/aac.26.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ganer A., Arathoon E., Stevens D. A. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S77–S86. doi: 10.1093/clinids/9.supplement_1.s77. [DOI] [PubMed] [Google Scholar]
  9. Graybill J. R., Craven P. C. Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs. 1983 Jan;25(1):41–62. doi: 10.2165/00003495-198325010-00003. [DOI] [PubMed] [Google Scholar]
  10. Graybill J. R., Craven P. C., Donovan W., Matthew E. B. Ketoconazole therapy for systemic fungal infections: inadequacy of standard dosage regimens. Am Rev Respir Dis. 1982 Jul;126(1):171–174. doi: 10.1164/arrd.1982.126.1.171. [DOI] [PubMed] [Google Scholar]
  11. Graybill J. R., Stevens D. A., Galgiani J. N., Dismukes W. E., Cloud G. A. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med. 1990 Sep;89(3):282–290. doi: 10.1016/0002-9343(90)90339-f. [DOI] [PubMed] [Google Scholar]
  12. Hardin T. C., Graybill J. R., Fetchick R., Woestenborghs R., Rinaldi M. G., Kuhn J. G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988 Sep;32(9):1310–1313. doi: 10.1128/aac.32.9.1310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Heiberg J. K., Svejgaard E. Toxic hepatis during ketoconazole treatment. Br Med J (Clin Res Ed) 1981 Sep 26;283(6295):825–826. doi: 10.1136/bmj.283.6295.825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Janssen P. A., Symoens J. E. Hepatic reactions during ketoconazole treatment. Am J Med. 1983 Jan 24;74(1B):80–85. doi: 10.1016/0002-9343(83)90519-3. [DOI] [PubMed] [Google Scholar]
  15. Kan P. B., Hirst M. A., Feldman D. Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. J Steroid Biochem. 1985 Dec;23(6A):1023–1029. doi: 10.1016/0022-4731(85)90062-7. [DOI] [PubMed] [Google Scholar]
  16. Lake-Bakaar G., Quadros E., Beidas S., Elsakr M., Tom W., Wilson D. E., Dincsoy H. P., Cohen P., Straus E. W. Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988 Sep 15;109(6):502–504. doi: 10.7326/0003-4819-109-6-502. [DOI] [PubMed] [Google Scholar]
  17. Lake-Bakaar G., Tom W., Lake-Bakaar D., Gupta N., Beidas S., Elsakr M., Straus E. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988 Sep 15;109(6):471–473. doi: 10.7326/0003-4819-109-6-471. [DOI] [PubMed] [Google Scholar]
  18. Lewis J. H., Zimmerman H. J., Benson G. D., Ishak K. G. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984 Mar;86(3):503–513. [PubMed] [Google Scholar]
  19. Loose D. S., Kan P. B., Hirst M. A., Marcus R. A., Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983 May;71(5):1495–1499. doi: 10.1172/JCI110903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Maskin S. L., Fetchick R. J., Leone C. R., Jr, Sharkey P. K., Rinaldi M. G. Bipolaris hawaiiensis-caused phaeohyphomycotic orbitopathy. A devastating fungal sinusitis in an apparently immunocompetent host. Ophthalmology. 1989 Feb;96(2):175–179. doi: 10.1016/s0161-6420(89)32917-4. [DOI] [PubMed] [Google Scholar]
  21. Negroni R., Palmieri O., Koren F., Tiraboschi I. N., Galimberti R. L. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S47–S50. doi: 10.1093/clinids/9.supplement_1.s47. [DOI] [PubMed] [Google Scholar]
  22. Perfect J. R., Durack D. T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. doi: 10.1093/jac/16.1.81. [DOI] [PubMed] [Google Scholar]
  23. Phillips P., Fetchick R., Weisman I., Foshee S., Graybill J. R. Tolerance to and efficacy of itraconazole in treatment of systemic mycoses: preliminary results. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S87–S93. doi: 10.1093/clinids/9.supplement_1.s87. [DOI] [PubMed] [Google Scholar]
  24. Phillips P., Graybill J. R., Fetchick R., Dunn J. F. Adrenal response to corticotropin during therapy with itraconazole. Antimicrob Agents Chemother. 1987 Apr;31(4):647–649. doi: 10.1128/aac.31.4.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pont A., Graybill J. R., Craven P. C., Galgiani J. N., Dismukes W. E., Reitz R. E., Stevens D. A. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984 Nov;144(11):2150–2153. [PubMed] [Google Scholar]
  26. Pont A., Williams P. L., Azhar S., Reitz R. E., Bochra C., Smith E. R., Stevens D. A. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982 Nov;142(12):2137–2140. [PubMed] [Google Scholar]
  27. Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra C., Stevens D. A. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. doi: 10.7326/0003-4819-97-3-370. [DOI] [PubMed] [Google Scholar]
  28. Restrepo A., Gomez I., Robledo J., Patiño M. M., Cano L. E. Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S51–S56. doi: 10.1093/clinids/9.supplement_1.s51. [DOI] [PubMed] [Google Scholar]
  29. Restrepo A., Robledo J., Gómez I., Tabares A. M., Gutiérrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol. 1986 Apr;122(4):413–417. [PubMed] [Google Scholar]
  30. Santen R. J., Van den Bossche H., Symoens J., Brugmans J., DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983 Oct;57(4):732–736. doi: 10.1210/jcem-57-4-732. [DOI] [PubMed] [Google Scholar]
  31. Sharkey P. K., Graybill J. R., Rinaldi M. G., Stevens D. A., Tucker R. M., Peterie J. D., Hoeprich P. D., Greer D. L., Frenkel L., Counts G. W. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol. 1990 Sep;23(3 Pt 2):577–586. doi: 10.1016/0190-9622(90)70259-k. [DOI] [PubMed] [Google Scholar]
  32. Sobel J. D., Muller G. Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother. 1984 Aug;26(2):266–267. doi: 10.1128/aac.26.2.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987 Sep 24;317(13):812–818. doi: 10.1056/NEJM198709243171307. [DOI] [PubMed] [Google Scholar]
  34. Tucker R. M., Williams P. L., Arathoon E. G., Stevens D. A. Treatment of mycoses with itraconazole. Ann N Y Acad Sci. 1988;544:451–470. doi: 10.1111/j.1749-6632.1988.tb40443.x. [DOI] [PubMed] [Google Scholar]
  35. Tucker W. S., Jr, Snell B. B., Island D. P., Gregg C. R. Reversible adrenal insufficiency induced by ketoconazole. JAMA. 1985 Apr 26;253(16):2413–2414. [PubMed] [Google Scholar]
  36. Van Cauteren H., Heykants J., De Coster R., Cauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S43–S46. doi: 10.1093/clinids/9.supplement_1.s43. [DOI] [PubMed] [Google Scholar]
  37. Van Cutsem J., Van Gerven F., Janssen P. A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S15–S32. doi: 10.1093/clinids/9.supplement_1.s15. [DOI] [PubMed] [Google Scholar]
  38. Van den Bossche H., Willemsens G., Cools W., Cornelissen F., Lauwers W. F., van Cutsem J. M. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother. 1980 Jun;17(6):922–928. doi: 10.1128/aac.17.6.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Viviani M. A., Tortorano A. M., Giani P. C., Arici C., Goglio A., Crocchiolo P., Almaviva M. Itraconazole for cryptococcal infection in the acquired immunodeficiency syndrome. Ann Intern Med. 1987 Jan;106(1):166–166. doi: 10.7326/0003-4819-106-1-166_1. [DOI] [PubMed] [Google Scholar]
  40. Warnock D. W., Turner A., Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother. 1988 Jan;21(1):93–100. doi: 10.1093/jac/21.1.93. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES